MedTrace Logo

Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)

NCT01947309 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 176

Last updated 2017-01-12

No results posted yet for this study

Summary

The primary objective of this study is to document efficacy and safety data in a real-world setting of Chinese multiple myeloma patients who have received at least one prior therapy treated with REVLIMID (lenalidomide).

Conditions

Interventions

DRUG

Revlimid (lenalidomide)

Revlimid (lenalidomide) as prescribed in usual clinical practice

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Yu (Flora) Yao, MD · Celgene Pharmaceutical (Shanghai) Co. Ltd.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2016-07-31
Completion
2016-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01947309 on ClinicalTrials.gov